Valuation : AbbVie Inc.

Market Cap 453B 390B 367B 335B 627B 42,789B 629B 4,336B 1,682B 21,954B 1,702B 1,665B 70,724B P/E 2026 *
32.7x
P/E 2027 * 24.2x
Enterprise Value 514B 442B 416B 380B 711B 48,500B 713B 4,914B 1,907B 24,884B 1,929B 1,887B 80,164B EV / Sales 2026 *
7.6x
EV / Sales 2027 * 6.87x
Free-Float
95.71%
Yield 2026 *
2.67%
Yield 2027 * 2.81%
09-03 AbbVie Announces Positive Topline Results From The Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma CI
09-03 AbbVie Inc. completed the acquisition of Apogee Therapeutics, Inc. from Fairmount Healthcare Fund II L.P managed by Fairmount Funds Management LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P managed by Venrock Management, LLC and other shareholders. CI
09-03 AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints MT
09-03 AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study DJ
09-03 AbbVie's blood cancer therapy lowers disease progression, death risk in trial RE
09-03 AbbVie's blood cancer drug meets late-stage trial goals RE
09-03 AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics MT
09-01 Global pharma companies that have publicly announced Trump drug pricing agreements RE
09-01 AbbVie Inc Receives Determination From Food And Drug Administration Regarding NAMENDA (Memantine Hydrochloride) Tablets 5 Mg And 10 Mg CI
08-27 AbbVie Seeks EU Approval for Subcutaneous Skyrizi Induction in Crohn's Disease MT
08-27 AbbVie Seeks European Regulatory Nod to Use Skyrizi as Subcutaneous Induction for Crohn's Disease Treatment MT
08-27 AbbVie Submits Regulatory Application To EMA For SKYRIZI (Risankizumab) Subcutaneous Induction For Adults With Moderately To Severely Active Crohn's Disease CI
08-26 Gubra Flags $50 Million Milestone Payment as AbbVie Begins Phase 2 Study of Obesity Drug MT
1 day-1.44%
1 week+0.38%
Current month+0.02%
1 month+5.19%
3 months+14.01%
6 months+8.58%
Current year+12.24%
1 week 252.33
Extreme 252.33
264.25
1 month 241.2
Extreme 241.2
266.96
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 A Exercice

Executive/Senior Manager

98,130 0.0056%
6/30/26 A Free

Director

62 0.0000%
6/30/26 A Free

Director

134 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%+0.38%+20.40%+73.05% 453B
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
-1.25%+1.75%+15.93%-20.49% 162B
Average -0.83%+1.16%+27.06%+43.97% 384.05B
Weighted average by Cap. -1.03%+0.60%+35.75%+62.56%

Financials

2026 *2027 *
Net sales 67.58B 58.16B 54.72B 49.98B 93.51B 6,381B 93.76B 647B 251B 3,274B 254B 248B 10,547B 73.52B 63.26B 59.52B 54.37B 102B 6,941B 102B 703B 273B 3,561B 276B 270B 11,473B
Net income 13.86B 11.93B 11.22B 10.25B 19.18B 1,309B 19.23B 133B 51.46B 671B 52.05B 50.92B 2,163B 18.91B 16.28B 15.31B 13.99B 26.17B 1,786B 26.24B 181B 70.22B 916B 71.02B 69.47B 2,952B
Net Debt 60.49B 52.05B 48.97B 44.74B 83.69B 5,711B 83.92B 579B 225B 2,930B 227B 222B 9,440B 51.66B 44.45B 41.83B 38.21B 71.47B 4,878B 71.67B 494B 192B 2,503B 194B 190B 8,062B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
04/09/26 $256.46 -1.44% 4,729,800
03/09/26 $260.21 -0.58% 2,878,739
02/09/26 $261.72 +0.67% 4,225,524
01/09/26 $259.99 +1.39% 3,866,739
31/08/26 $256.42 +0.37% 4,315,487
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
256.46USD
Average target price
276.59USD
Spread / Average Target
+7.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock